| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
SGC-SMARCA-BRDVIII targets SMARCA2 (BRM) and SMARCA4 (BRG1), which are ATPase subunits of the SWI/SNF chromatin remodeling complex. These proteins are critical for regulating gene expression by remodeling chromatin structure. The compound also inhibits PB1(5) (PBRM1 bromodomain 5) with a Kd of 13 nM. It also inhibits PB1(2) and PB1(3) with Kds of 3.7 and 2.0 μM, respectively. By inhibiting these bromodomains, SGC-SMARCA-BRDVIII disrupts SWI/SNF complex function.
|
|---|---|
| ln Vitro |
SGC-SMARCA-BRDVIII (Compound 22) (1 μM; 14 days) Foam adipocyte secretions in murine fibroblasts 3T3-L1 [1].
In vitro, SGC-SMARCA-BRDVIII is a potent and specific inhibitor of SMARCA2/4 and PB1(5) with Kd values of 35 nM, 36 nM, and 13 nM, respectively. It also inhibits PB1(2) and PB1(3) with Kd values of 3.7 and 2.0 μM, respectively. The compound (1 μM; 14 days) blocks adipocyte differentiation in 3T3-L1 murine fibroblasts. Its selective inhibition of SMARCA2/4 bromodomains makes it valuable for studying SWI/SNF biology. |
| ln Vivo |
In vivo, SGC-SMARCA-BRDVIII has potential applications in studying SWI/SNF chromatin remodeling complex function and related diseases. However, specific in vivo efficacy data for SGC-SMARCA-BRDVIII have not been detailed in the available literature. The compound is a chemical probe designed for research into epigenetic regulation and SWI/SNF complex biology. Further preclinical studies would be required.
|
| Enzyme Assay |
For in vitro binding assays, recombinant bromodomain proteins (SMARCA2, SMARCA4, PBRM1 BD5, PBRM1 BD2, PBRM1 BD3) are incubated with fluorescently labeled or radiolabeled ligands at various concentrations of SGC-SMARCA-BRDVIII (0.1-1000 nM). Binding affinity (Kd) is determined using surface plasmon resonance (SPR), isothermal titration calorimetry (ITC), or fluorescence polarization assays.
|
| Cell Assay |
For cell-based assays, 3T3-L1 murine fibroblasts or other relevant cell types are treated with SGC-SMARCA-BRDVIII at concentrations ranging from 0.1-10 µM for up to 14 days. Adipocyte differentiation is assessed by Oil Red O staining and by measuring the expression of adipogenic markers. SWI/SNF complex function can be assessed by analyzing chromatin accessibility and gene expression.
|
| Animal Protocol |
For in vivo studies, animal models of diseases involving SWI/SNF dysfunction would be used. SGC-SMARCA-BRDVIII would be administered via appropriate routes at doses determined from pharmacokinetic studies. However, specific in vivo protocols for SGC-SMARCA-BRDVIII have not been detailed in the available literature. The compound is primarily used as a chemical probe for in vitro studies.
|
| ADME/Pharmacokinetics |
SGC-SMARCA-BRDVIII is soluble in DMSO. Storage is recommended at -20°C for long-term stability. Further detailed PK parameters including half-life, oral bioavailability, and tissue distribution would be required for in vivo studies. The compound is for research use only and is not intended for human or veterinary use.
|
| Toxicity/Toxicokinetics |
Toxicological data for SGC-SMARCA-BRDVIII have not been extensively reported. As a research compound, it is intended for laboratory use only and is not for human or veterinary use. Standard safety precautions should be followed when handling this compound. Comprehensive toxicology studies would be required before any clinical development.
|
| References | |
| Additional Infomation |
SGC-SMARCA-BRDVIII is a potent and selective SMARCA2/4 BRD inhibitor with Kd values of 35 nM (SMARCA2), 36 nM (SMARCA4), and 13 nM (PB1(5)). It also inhibits PB1(2) and PB1(3). The compound blocks adipocyte differentiation in 3T3-L1 fibroblasts. SGC-SMARCA-BRDVIII is a research tool and is not approved for clinical use.
|
| Molecular Formula |
C19H25N5O3
|
|---|---|
| Molecular Weight |
371.43
|
| Exact Mass |
371.2
|
| Elemental Analysis |
C, 61.44; H, 6.78; N, 18.85; O, 12.92
|
| CAS # |
1997319-84-2
|
| Related CAS # |
1997319-84-2;
|
| PubChem CID |
137045929
|
| Appearance |
Off-white to yellow solid powder
|
| LogP |
1.6
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
27
|
| Complexity |
504
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC(C)(C)OC(=O)N1CCN(CC1)C2=CC(=NN=C2N)C3=CC=CC=C3O
|
| InChi Key |
AQTNUGRRZDRZIA-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C19H25N5O3/c1-19(2,3)27-18(26)24-10-8-23(9-11-24)15-12-14(21-22-17(15)20)13-6-4-5-7-16(13)25/h4-7,12,25H,8-11H2,1-3H3,(H2,20,22)
|
| Chemical Name |
tert-butyl 4-[3-amino-6-(2-hydroxyphenyl)pyridazin-4-yl]piperazine-1-carboxylate
|
| Synonyms |
SGC-SMARCA-BRDVIII; SGCSMARCABRDVIII; SGC SMARCA BRDVIII;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~25 mg/mL (~67.31 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.73 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.73 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (6.73 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6923 mL | 13.4615 mL | 26.9230 mL | |
| 5 mM | 0.5385 mL | 2.6923 mL | 5.3846 mL | |
| 10 mM | 0.2692 mL | 1.3461 mL | 2.6923 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
